RBC Capital analyst Simos Simeonidis cut his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $5.00 (from $7.00) following an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Sarepta Therapeutics (SRPT) Continues Grind Higher from Morning LowsApril 26, 2016 12:45 PM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightApril 26, 2016 7:28 AM Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next YearApril 26, 2016 7:23 AM Sarepta Therapeutics (SRPT) Resumes Trading; Shares down 53%April 26, 2016 7:11 AM Sarepta Therapeutics (SRPT) to resume trading at 7:10AM ETApril 26, 2016 7:07 AM Sarepta Therapeutic (SRPT) PT Cut to $7 at Jefferies Following Negative AdComApril 26, 2016 6:49 AM Oppenheimer Downgrades Sarepta Therapeutic (SRPT) to PerformApril 26, 2016 6:40 AM Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMDApril 26, 2016 5:58 AM Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular DystrophyApril 25, 2016 10:58 PM FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)April 25, 2016 6:12 PM